Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q2 2020 · 10-Q
Revenue$0.00$0.00derivedno prior Q2 2019 on file Net Income-$380.03K-$380.03KN/M vs Q2 2019 EPS Diluted-$0.05-$0.05N/M vs Q2 2019 Operating Income-$132,709N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
Operating Cash Flowderived-$79,134N/M ended Jun 30, 2020 · filed Apr 15, 2021 · 289 d after period end